EA202092691A1 - Соединения для устранения боли, композиции, содержащие их, и способы их применения - Google Patents

Соединения для устранения боли, композиции, содержащие их, и способы их применения

Info

Publication number
EA202092691A1
EA202092691A1 EA202092691A EA202092691A EA202092691A1 EA 202092691 A1 EA202092691 A1 EA 202092691A1 EA 202092691 A EA202092691 A EA 202092691A EA 202092691 A EA202092691 A EA 202092691A EA 202092691 A1 EA202092691 A1 EA 202092691A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
application
pain relief
opioid
Prior art date
Application number
EA202092691A
Other languages
English (en)
Inventor
Скотт Л. Дэкс
Паскуале Н. Конфалоне
Original Assignee
Церси Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Церси Терапьютикс, Инк. filed Critical Церси Терапьютикс, Инк.
Publication of EA202092691A1 publication Critical patent/EA202092691A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединениям формулы (I), композициям, содержащих их, и способам, предназначенным для устранения и/или уменьшения боли у субъекта, нуждающегося в этом. Соединения формулы (I) являются эффективными для лечения опиоид-индуцированной тахифилаксии и опиоид-индуцированной гипералгезии.
EA202092691A 2018-05-29 2019-05-20 Соединения для устранения боли, композиции, содержащие их, и способы их применения EA202092691A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862677496P 2018-05-29 2018-05-29
PCT/US2019/033140 WO2019231739A1 (en) 2018-05-29 2019-05-20 Compounds for pain treatment, compositions comprising same, and methods of using same

Publications (1)

Publication Number Publication Date
EA202092691A1 true EA202092691A1 (ru) 2021-04-21

Family

ID=66770595

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092691A EA202092691A1 (ru) 2018-05-29 2019-05-20 Соединения для устранения боли, композиции, содержащие их, и способы их применения

Country Status (14)

Country Link
US (3) US11091473B2 (ru)
EP (1) EP3802524A1 (ru)
JP (1) JP2021525269A (ru)
KR (1) KR20210015892A (ru)
CN (1) CN112204025B (ru)
AU (1) AU2019279761A1 (ru)
BR (1) BR112020024261B8 (ru)
CA (1) CA3101738A1 (ru)
EA (1) EA202092691A1 (ru)
IL (1) IL278904A (ru)
MX (1) MX2020012805A (ru)
SG (1) SG11202011534YA (ru)
WO (1) WO2019231739A1 (ru)
ZA (1) ZA202007320B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022265960A1 (en) * 2021-06-13 2022-12-22 Daya Drug Discoveries, Inc. Prevention and treatment of neuronal damage with pyridoindolobenz[b, d] azepine compositions
WO2022266211A1 (en) * 2021-06-17 2022-12-22 Acadia Pharmaceuticals Inc. Methods of treating, ameliorating, and/or preventing osteoarthritic pain

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
FR2581063B1 (fr) 1985-04-30 1987-07-17 Chauvin Blache Lab Amino-2 thiazoles n-substitues, leur procede de preparation et leur application en therapeutique
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
WO1993018755A1 (en) 1992-03-25 1993-09-30 Depomed Systems, Incorporated Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5840739A (en) 1992-11-16 1998-11-24 University Of Florida Research Foundation, Inc. Thiazoline acid derivatives
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
JP4083818B2 (ja) 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
EP1790334A3 (en) 1999-11-02 2008-02-20 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
IL150568A0 (en) 2000-02-04 2003-02-12 Depomed Inc A controlled release oral drug dosage form
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
MXPA03011096A (es) 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US7413751B2 (en) 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20040132789A1 (en) * 2002-08-22 2004-07-08 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
GB0508463D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
NL2003786C2 (en) 2009-11-11 2010-07-30 Medner B V COMPOSITION FOR TOPICAL APPLICATION, USES THEREOF, APPLICATOR DEVICE AND KIT OF PARTS.
CN102858176A (zh) 2010-03-10 2013-01-02 加林制药公司 镇痛化合物、组合物及其应用
EP3070084A1 (en) * 2015-03-18 2016-09-21 Rottapharm Biotech S.r.l. New fyn kinase inhibitors
JP7104702B2 (ja) 2016-12-01 2022-07-21 プロメガ コーポレイション ５，５－二置換ルシフェリン及びルシフェラーゼ系アッセイにおけるそれらの使用

Also Published As

Publication number Publication date
WO2019231739A1 (en) 2019-12-05
CA3101738A1 (en) 2019-12-05
AU2019279761A1 (en) 2020-12-10
US20190367499A1 (en) 2019-12-05
SG11202011534YA (en) 2020-12-30
BR112020024261B8 (pt) 2022-05-17
IL278904A (en) 2021-01-31
US20200131170A1 (en) 2020-04-30
CN112204025A (zh) 2021-01-08
US10844054B2 (en) 2020-11-24
US11091473B2 (en) 2021-08-17
MX2020012805A (es) 2021-02-15
CN112204025B (zh) 2022-05-31
JP2021525269A (ja) 2021-09-24
BR112020024261B1 (pt) 2022-05-03
EP3802524A1 (en) 2021-04-14
BR112020024261A2 (pt) 2021-02-23
US20220153731A1 (en) 2022-05-19
ZA202007320B (en) 2022-04-28
KR20210015892A (ko) 2021-02-10

Similar Documents

Publication Publication Date Title
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
SA522433087B1 (ar) Sos1 مثبطات
EA201890161A1 (ru) Терапевтические композиции, комбинации и способы применения
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
EA202091186A1 (ru) ИНГИБИТОРЫ KRas G12C
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
EA201890247A1 (ru) Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
EA201992137A1 (ru) ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1
EA202192394A1 (ru) Ингибиторы пути передачи сигнала notch и их применение для лечения рака
EA201990508A1 (ru) ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
EA202092691A1 (ru) Соединения для устранения боли, композиции, содержащие их, и способы их применения
EA202190766A1 (ru) Иммуномодуляторы, их композиции и способы применения
EA202092446A1 (ru) ТИАЗОЛ- ИЛИ ТИАДИАЗОЛЗАМЕЩЕННЫЕ АРИЛЬНЫЕ И ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ Vps34
EA202092045A1 (ru) Лечение и предупреждение преэклампсии
EA201800565A1 (ru) Композиция для лечения заболеваний уха, содержащая (+)-азасетрон
EA201990041A1 (ru) Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении